Researchers have uncovered two key brain mechanisms—specific neurons and a serotonin receptor—that help explain how psilocybin produces long-lasting antidepressant effects.
CTSC-activated fluorescence probes enable rapid sorting of benign/malignant breast tumors.
Ketorolac in the perioperative management of acute type A aortic dissection: a randomized double-blind placebo-controlled trial
Posted in biotech/medical | Leave a Comment on Ketorolac in the perioperative management of acute type A aortic dissection: a randomized double-blind placebo-controlled trial
Acute Type A Aortic Dissection (aTAAD) is a severe and life-threatening condition. While animal studies have suggested that ketorolac could slow the progression of aortic aneurysms and dissections, clinical data on its efficacy in aTAAD patients remain limited. This study seeks to evaluate the safety and effectiveness of ketorolac in this patient group.
Patients were randomly assigned to receive either ketorolac or a placebo (0.9% saline). Treatment began at least 2 h prior to surgery (60 mg ketorolac or 2 ml saline administered once intramuscularly) and continued for 48 h post-surgery (30 mg ketorolac or 1 ml saline administered intramuscularly twice daily). The primary endpoints included assessing the safety and efficacy of ketorolac in improving the prognosis of aTAAD, focusing on mortality and organ malperfusion syndrome. Secondary endpoints included drug-related adverse events, blood test results, and other postoperative outcomes.
Of 179 patients who underwent aTAAD repair, 110 met the inclusion criteria and were randomized into two groups of 55. One patient discontinued the intervention due to erythroderma on the first postoperative day, leaving 54 patients in the ketorolac group and 55 in the placebo group for analysis. No significant differences were found in the primary endpoints. However, the ketorolac group showed lower intraoperative bleeding (median: 1.8 L vs. 2.0 L, P = 0.03), shorter intensive care unit (ICU) stays (median: 6.5 days vs. 8 days, P = 0.04), and lower total hospital costs (median: ¥170,430 vs. ¥187,730, P = 0.03).
Now online!By using an engineered human-iPSC-derived muscle progenitor model, it is shown that PAX fusion transcription factors remodel 3D chromatin maps and transcriptional circuits to activate oncogenes and drive mitochondrial OXPHOS in high-risk rhabdomyosarcoma.
In a first, physicists have directly seen Hofstadter’s butterfly—a long-sought-after fractal in the quantum realm
Allogeneic cell therapeutics are currently being developed to overcome manufacturing bottlenecks of autologous products but face allorejection as their biggest obstacle. This review analyzes the immunogenicity of allogeneic cell therapeutics, outlines engineering strategies for immune evasion, and summarizes recent milestone achievements.
Researchers categorized participants by whether or not they had experienced SCD, and by their antidepressant medication use — between 1 and 5 years, or 6 years and longer.
At the study’s conclusion, researchers found that participants who used antidepressants for a period of 1 to 5 years had a 56% increased risk of SCD.
Participants who used antidepressants for 6 or more years had a 2.2 times higher risk for SCD.
A new study from Cedars-Sinai has examined whether a specialized diet could improve symptoms of gastrointestinal disorders linked to an imbalance in gut microbiota.
The research tested the elemental diet’s effectiveness and explored whether improving its unappealing taste—a major barrier—could help patients adhere to the diet’s stringent protocol. The investigators’ findings were published in the peer-reviewed journal Clinical Gastroenterology and Hepatology.
The elemental diet is a special low-fat liquid formulation that is designed to be easily digested and contains all the essential nutrients necessary for a healthy diet. A few prior studies have shown that the diet has the potential to improve challenging symptoms associated with digestive issues like small intestinal bacterial overgrowth (SIBO), intestinal methanogen overgrowth (IMO), Crohn’s disease, eosinophilic esophagitis and other gut ailments.
By doing more and more of our “thinking” for us, artificial intelligence may be diminishing our critical thinking skills.
There is an urgent need for precision immunotherapy strategies that simultaneously target both tumor cells and immune cells to enhance treatment efficacy. Identifying genes with dual functions in both cancer and immune cells opens new possibilities for overcoming tumor resistance and improving patient survival.
Professor Zeng Zexian’s team from the Center for Quantitative Biology at the Peking University Academy for Advanced Interdisciplinary Studies, in collaboration with the Peking University-Tsinghua University Joint Center for Life Sciences, has developed ICRAFT, an innovative computational platform for identifying cancer immunotherapy targets. Their study has been published in Immunity.
ICRAFT integrates 558 CRISPR screening datasets, 2 million single-cell RNA sequencing datasets, and 943 RNA-Seq datasets from clinical immunotherapy samples.